News

Can-Fite BioPharma Secures $15 Million in Public Funding

Can-Fite BioPharma Secures $15 Million in Public Funding

Can-Fite BioPharma Secures Up To $15 Million in Public Offering

$5 million upfront, with an additional potential $10 million pending warrant exercise

Can-Fite BioPharma Ltd. (NYSE American: CANF), a clinical-stage biotechnology company specializing in innovative therapies for cancer and inflammatory diseases, has disclosed a recent public offering priced at $0.60 per share for institutional investors. The offering includes 8,333,333 American Depositary Shares (ADSs), alongside short-term warrants allowing for the purchase of an additional 16,666,666 ADSs.

Details of the Offering

According to the announcement, the company expects the gross proceeds from this offering to reach approximately $5 million, excluding fees related to the placement agent and other costs. Should the accompanying short-term warrants be fully exercised, an additional $10 million in gross proceeds may be realized.

This offering is positioned to close soon, pending satisfaction of standard closing conditions and the company is working with H.C. Wainwright & Co. as the placement agent for this transaction.

Utilization of Funds

Funds generated from this offering are intended for vital areas including research and development, clinical trials, and administrative expenses. This strategic approach underlines Can-Fite's commitment to advance their promising pipeline of drug candidates.

Company Overview

As a notable player in biopharmaceuticals, Can-Fite is focused on addressing substantial market opportunities within healthcare. Their noteworthy drug, Piclidenoson, is undergoing pivotal trials, demonstrating its potential in treating psoriasis. Preliminary results have yielded optimism for its efficacy and safety, which could pave the way for approvals in various markets.

In addition to Piclidenoson, Can-Fite is making significant strides with Namodenoson, a drug being investigated for treating hepatocellular carcinoma (HCC) through a Phase III trial, as well as potential applications in other cancers such as colon and prostate. This drug has already received Orphan Drug Designation and Fast Track Designation due to its promising profile.

Moreover, CF602, another drug candidate targeting erectile dysfunction, has also shown encouraging results. With a safety profile established through studies involving over 1,600 patients, Can-Fite is well-positioned to bring these therapies to market.

Contact Information

For further information or inquiries related to the offering, interested parties can reach out to Can-Fite BioPharma. Motti Farbstein can be contacted either via email at info@canfite.com or by phone at +972-3-9241114.

Frequently Asked Questions

What is the amount Can-Fite is looking to raise?

Can-Fite aims to raise up to $15 million through this public offering.

What will the funds be used for?

The funds will primarily support research and development efforts, clinical trials, and other operational needs.

Who is managing the public offering?

H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering.

What are the key drugs in Can-Fite’s pipeline?

Can-Fite is advancing several drug candidates, including Piclidenoson and Namodenoson, which target various cancers and inflammatory diseases.

How can I learn more about Can-Fite?

For detailed information, you can visit their official website or contact their office directly.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Berry Street Integrates AI with What Matters: Human Touch

Updated Category News Views 244

Health Meets AI at Berry Street In recent waves of news, Berry Street has decided to toss MyScribe, a standalone AI service, into its shopping cart and welcomed its brainwave behind it, Dr. Wasif Bokhari, into their corridors. Yep, they’ve snagged both the tech and the mind! It's the kind of move that makes you stop midway through your diner coffee. Here’s Berry...

Continue Reading
Ambrosia Biosciences Unveils Promising Nonclinical Metabolic Data

Updated Category News Views 385

Ambrosia's Latest Nonclinical Revelations Ambrosia Biosciences has just thrown out some major bait at ObesityWeek® 2026. The highlight? New nonclinical data profiles for two of their understudy small molecule programs—AMB-895 and AMB-131. It may sound niche, but in this sector, promising data spins heads. Their GLP-1 receptor agonist, AMB-895, and GIP receptor...

Continue Reading
Championing Change: USTA Mid-Atlantic Gala's Impact

Updated Category News Views 309

A Night to Remember: USTA Mid-Atlantic's Gala Who would've thought tennis could wield such transformative power? This ain't your average sport gala. Last Saturday, a crowd of over 300 gathered at the Ritz-Carlton Tysons Corner for the USTA Mid-Atlantic Foundation's 2026 Tennis Creates Gala. Hosted by the formidable Malika Andrews, this event wasn't just a fancy...

Continue Reading
Princess Cruises Launches New Era at Celebration Key

Updated Category News Views 185

Never thought I'd see the day when a cruise ship docking would stir such excitement, but here we are. The Star Princess has made its grand debut at Celebration Key, the latest jewel in Princess Cruises' crown. And they're going all out with Bahamian flair—something about a Junkanoo band and beach art that would make even the crustiest sailor crack a smile. Inaugural Fun...

Continue Reading
Investors Gear Up for Lennar Class Action Lawsuit

Updated Category News Views 322

High Stakes and Hard Hits for Lennar Stockholders There’s rarely a dull moment in the world of Wall Street, and Lennar Corporation (NYSE: LEN) is proving that rule right now. As a whiff of scandal wafts through the air, the famed homebuilder and its bigwigs are staring down the barrel of a formidable class action lawsuit. The question is, just how deep do the alleged...

Continue Reading
JOYEE N01 Debuts Globally with First 2,000 Deliveries

Updated Category News Views 324

JOYYE N01 Breaks into the Global Market Now, here we go, folks—a Chinese car with ambitions bigger than the Sahara. On October 28, the JOYEE N01 rolled off the assembly line and into the international scene with a lot of fanfare at FAW's Yancheng Branch. Mark my words, this isn't just another model trying to strut into the global auto arena. This event delivered the...

Continue Reading
Novo's CagriSema Trials Show Promising Weight Loss

Updated Category News Views 393

Decoding CagriSema's Promise Let me tell you, when those corporate folks from Novo Nordisk announce something big like their investigational drug CagriSema at ObesityWeek® 2026, it’s time to take notice. This isn’t just your average press release about some new weight loss fad. We’re talking about a phase 3 REDEFINE 1 trial that opens up a treasure chest of data...

Continue Reading
IDEAYA's IDE101: A New Front in Cancer Battle

Updated Category News Views 273

IDEAYA's Bold Move in Precision Medicine IDEAYA Biosciences, no stranger to the frontlines of cancer treatment, is gunning for a breakthrough with their latest pick, IDE101. They're jumping into the ring with a potential first-in-class inhibitor targeting CDKN2A-deficiency—a notorious player in the solid tumor game. They're not just mixing things up for the sake of it;...

Continue Reading
Portillo's Faces Class Action: Investor Losses at Stake

Updated Category News Views 234

Investor Tensions Rise as Portillo's Inc. Lawsuit Unfolds Investment ain't all sunshine and rainbows, and if you've been holding Portillo's Inc. (NASDAQ: PTLO) stocks between September 19, 2023, and May 4, 2026, you might find yourself caught in a storm front. We're talking shareholder class action lawsuit, folks, thanks to some allegedly misguided management moves. This...

Continue Reading
InstaHeat 35K: FOGATTI Offers Upgraded RV Furnace Control

Updated Category News Views 430

Winter RV Trips Just Got Cozier There's nothing quite like hitting the open road in an RV during the winter months. But let's face it, nobody wants to return to a cabin that's as frigid as the great outdoors. Here's where FOGATTI steps up its game with the InstaHeat Ultra 35K RV Furnace. They’ve tinkered with the thermostat to iron out more precise control, just in time...

Continue Reading

Top 5 Most Recently Viewed Articles

Banco Comercial Português Highlights Positive Share Buy-Back Activities

Updated Category News Views 137

Banco Comercial Português: An Overview of Recent Developments Banco Comercial Português, S.A., recognized for its pivotal role in the financial sector, has recently shared insights about its Share Buy-Back Programme. This initiative reflects the bank's commitment to enhancing shareholder value while solidifying its market presence. The interim report detailing the...

Continue Reading
How a $1000 Investment in Texas Instruments Transforms Over 15 Years

Updated Category News Views 135

Understanding the Growth of Texas Instruments Investments Texas Instruments (NASDAQ: TXN) has displayed impressive growth over the past 15 years, outpacing the market by an average of 2.3% annually. This translates to a robust average annual return of 14.17%, reflecting this company's strong position in the semiconductor industry. With a market capitalization now standing...

Continue Reading
Bitdeer Technologies Group's Q4 2024 Financial Overview

Updated Category News Views 204

Bitdeer Technologies Group's Financial Results Analysis Bitdeer Technologies Group (NASDAQ: BTDR), a prominent player in blockchain technology and high-performance computing, has recently unveiled its unaudited financial results for the final quarter of 2024. The announcement sheds light on the company's performance, revealing significant shifts in revenue and expenses...

Continue Reading
NodeAI Revolutionizes Lung Cancer Care with AI Solutions

Updated Category News Views 206

NodeAI's Groundbreaking Achievement in Cancer Diagnostics NodeAI, a pioneering startup based in Hamilton, Ontario, has recently garnered attention for its exceptional advancements in lung cancer diagnostics. The company participated in FACIT's annual pitch competition, known as Falcons' Fortunes, and emerged victorious, earning a prestigious award for its innovative...

Continue Reading
Runway Growth Capital Bolsters Leadership with Rovner

Updated Category News Views 72

A New Era for Runway Growth Capital Alright folks, here's the scoop for anyone tracking the moves in the growth lending space: Michael Rovner, with his hefty 30-year career in the financial sector, is now taking on the role of Co-Chief Executive Officer and Co-Chief Investment Officer at Runway Growth Capital. This guy's a veteran, no doubt, having navigated the overlaps...

Continue Reading